Last Updated on October 6, 2021 by The Health Master
The Indian Pharmacopoeia Commission (IPC), the National Coordination Centre (NCC) for Pharmacovigilance Programme of India (PvPI), has been redesignated as WHO collaborating centre for Pharmacovigilance in public health programmes and regulatory services.
IPC will support WHO through centre to develop relevant tools and guidelines for enhancing Pharmacovigilance (PV) practice in low and middle income countries (LMIC) in Asia and beyond by contributing to its work to build capacity of WHO Member States to establish high quality pharmacovigilance systems for medical products including medical devices.
It will also support WHO by contributing to its work guiding countries in the integration of pharmacovigilance in public health programmes such as tuberculosis, neglected tropical diseases, vector borne diseases, HIV-AIDS; immunization programme and regulatory issues.
The WHO collaborating centre will work in the areas of pharmaceuticals (including essential drugs and medicines) and health systems research and development.
The types of activities involved by the Centre include training and education, development and application of appropriate technology providing technical advice to WHO.
The Pharmacovigilance Programme of India is an Indian government organization which identifies and responds to drug safety problems. Its activities include receiving reports of adverse drug events and taking necessary action to remedy problems.
The establishment of the Pharmacovigilance Programme made India a more attractive international destination for foreign companies to bring clinical trials research.
Indian Pharmacopoeia Commission is an autonomous Institution of the ministry of health and family welfare, Government of India. IPC is created to set standards of drugs in the country.
Its basic function is to update regularly the standards of drugs commonly required for treatment of diseases prevailing in this region.
The mandate of the Commission is to perform, inter-alia, functions such as revision and publication of the Indian Pharmacopoeia and National Formulary of India on a regular basis besides providing IP reference substances and training to the stakeholders on pharmacopoeial issues.